Brighter carries out a private placement of 39.7 MSEK

The Board of Directors of Brighter has, under the authorization from the AGM of 2020, decided on a new share issue of a total of 39.7 MSEK. Payment will be made in cash. The amount of cash received will be used in full to repay previous loans from these lenders and the right to participate in the issue is only given to the lenders. The reasons for the deviation from the shareholders' preferential rights are to strengthen the company's financial position, which the issue is deemed to entail.  

Issue terms: 

• 10% discount on the lowest volume-weighted average price of the share during the period of the 15 days, July 9 to July 29, 2021. The subscription price is 1.042 SEK. The subscription price is calculated from the conversion right in the loan agreement. 
   
• The number of shares in the company increased by 38,095,755, to a total of 390,311,348. The share capital increases by 1,904,787.75 SEK to a total of 19,515,567.40 SEK

Investor Relations
ir@brighter.se 

Certified Adviser
Brighter's Certified Adviser is Eminova Fondkommission AB
+46 (0)8 - 684 211 10
adviser@eminova.se
www.eminova.se

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is a key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019, the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
For more information, please visit our website at https://brighter.se

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on August 8 at 22:00 CET